Rapid and accurate ranking of binding affinities of epidermal growth factor receptor sequences with selected lung cancer drugs.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 21227963.
- Also identified by DOI 10.1098/rsif.2010.0609 and PMC identifier 3119879.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The epidermal growth factor receptor (EGFR) is a major target for drugs in treating lung carcinoma. Mutations in the tyrosine kinase domain of EGFR commonly arise in human cancers, which can cause drug sensitivity or resistance by influencing the relative strengths of drug and ATP-binding. In this study, we investigate the binding affinities of two tyrosine kinase inhibitors--AEE788 and Gefitinib--to EGFR using molecular dynamics simulation. The interactions between these inhibitors and the EGFR kinase domain are analysed using multiple short (ensemble) simulations and the molecular mechanics/Poisson-Boltzmann solvent area (MM/PBSA) method. Here, we show that ensemble simulations correctly rank the binding affinities for these systems: we report the successful ranking of each drug binding to a variety of EGFR sequences and of the two drugs binding to a given sequence, using petascale computing resources, within a few days.
Medical subject headings
- Computer Simulation
- ErbB Receptors
- Lung Neoplasms
- Models, Molecular
- Mutation
- Neoplasm Proteins
- Protein Kinase Inhibitors
- Purines
- Quinazolines